Systemic Levels of Pro-Inflammatory Cytokines and Post-Treatment Modulation in Tuberculous Lymphadenitis

Author:

Kathamuthu Gokul Raj123ORCID,Moideen Kadar1,Sridhar Rathinam4,Baskaran Dhanaraj2,Babu Subash15

Affiliation:

1. National Institutes of Health-NIRT-International Center for Excellence in Research, Chennai 600 031, India

2. National Institute for Research in Tuberculosis (NIRT), Chennai 600 031, India

3. Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, 171 77 Solna, Sweden

4. Government Stanley Medical Hospital, Chennai 600 001, India

5. Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892-0425, USA

Abstract

Pro-inflammatory cytokines are potent stimulators of inflammation and immunity and markers of infection severity and bacteriological burden in pulmonary tuberculosis (PTB). Interferons could have both host-protective and detrimental effects on tuberculosis disease. However, their role has not been studied in tuberculous lymphadenitis (TBL). Thus, we evaluated the systemic pro-inflammatory (interleukin (IL)-12, IL-23, interferon (IFN)α, and IFNβ) cytokine levels in TBL, latent tuberculosis (LTBI), and healthy control (HC) individuals. In addition, we also measured the baseline (BL) and post-treatment (PT) systemic levels in TBL individuals. We demonstrate that TBL individuals are characterized by increased pro-inflammatory (IL-12, IL-23, IFNα, IFNβ) cytokines when compared to LTBI and HC individuals. We also show that after anti-tuberculosis treatment (ATT) completion, the systemic levels of pro-inflammatory cytokines were significantly modulated in TBL individuals. A receiver operating characteristic (ROC) analysis revealed IL-23, IFNα, and IFNβ significantly discriminated TBL disease from LTBI and/or HC individuals. Hence, our study demonstrates the altered systemic levels of pro-inflammatory cytokines and their reversal after ATT, suggesting that they are markers of disease pathogenesis/severity and altered immune regulation in TBL disease.

Funder

Division of Intramural Research, NIAID, NIH

Publisher

MDPI AG

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Immunology and Microbiology

Reference51 articles.

1. WHO Publication (2023, January 10). Global Tuberculosis Report 2022. Available online: https://www.who.int/health-topics/tuberculosis#tab=tab_1.

2. Index—TB guidelines: Guidelines on extrapulmonary tuberculosis for India;Sharma;Indian J. Med. Res.,2017

3. Current diagnosis and management of peripheral tuberculous lymphadenitis;Fontanilla;Clin. Infect. Dis.,2011

4. Nodal tuberculosis revisited: A review;Handa;J. Infect. Dev. Ctries.,2012

5. Identification of risk factors for extrapulmonary tuberculosis;Yang;Clin. Infect. Dis.,2004

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Electrolyte disruption in drug-resistant tuberculosis: Managing risks for improved treatment outcomes;IP Indian Journal of Immunology and Respiratory Medicine;2024-07-15

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3